Reporting owner · CIK 0001830001
Wolfe Josh
Visual SEC Form 4 history across 1 companies, 28 transactions and 2 filings.
DIREikon Therapeutics, Inc.
Open-market mix
100%buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #51952 | EIKN | Wolfe Josh | DIR | C | 10.2M | — | C | 02/06 | 02/06 |
| #51951 | EIKN | Wolfe Josh | DIR | C | 1.45M | — | C | 02/06 | 02/06 |
| #51950 | EIKN | Wolfe Josh | DIR | C | 303k | — | C | 02/06 | 02/06 |
| #51949 | EIKN | Wolfe Josh | DIR | C | 3.52M | — | C | 02/06 | 02/06 |
| #51948 | EIKN | Wolfe Josh | DIR | C | 5.28M | — | C | 02/06 | 02/06 |
| #51947 | EIKN | Wolfe Josh | DIR | C | 530k | — | C | 02/06 | 02/06 |
| #51946 | EIKN | Wolfe Josh | DIR | C | 796k | — | C | 02/06 | 02/06 |
| #51945 | EIKN | Wolfe Josh | DIR | C | 2.50M | — | C | 02/06 | 02/06 |
| #51944 | EIKN | Wolfe Josh | DIR | C | 7.80M | — | C | 02/06 | 02/06 |
| #51943 | EIKN | Wolfe Josh | DIR | C | 10.0M | — | C | 02/06 | 02/06 |
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at Eikon Therapeutics, Inc. on Feb 04, 2026 valued at $2,499,984.
Review SEC filingLatest sale
No open-market insider sale is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · Feb 4, 2026 – Feb 6, 2026. Window ends at the latest available report, not today.
Selected observation · Feb 6, 20262,294,653 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Feb 4, 2026 | 138,888 | Feb 6, 2026 | View transaction |
| Feb 6, 2026 | 2,387,705 | Feb 6, 2026 | View transaction |
| Feb 6, 2026 | 1,290,428 | Feb 6, 2026 | View transaction |
| Feb 6, 2026 | 2,294,653 | Feb 6, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Feb 26
$5M
Transaction texture
Ownership and ticket size
Average P/S size$2.5M
Median P/S size$2.5M
Direct0
Indirect28
Feb 06, 2026C
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
Wolfe Josh Insider Activity FAQ
SEC Form 4 context
Who is Wolfe Josh?
Wolfe Josh is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001830001.
Which companies has Wolfe Josh reported transactions for?
Eikon Therapeutics, Inc.
When was Wolfe Josh's latest insider buy?
buy at Eikon Therapeutics, Inc. on Feb 04, 2026 valued at $2,499,984.
When was Wolfe Josh's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.